Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease
|
February 2, 2018
Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials
David B Rubin, Harris A Ahmad, Michael O'Neal, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
November 23, 2018
Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
Salman H Siddiqui, Ian D Pavord, Neil C Barnes, et al.
Chest
|
January 14, 2012
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial
Nicola A Hanania, Gregory Feldman, Wolfgang Zachgo, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
July 1, 2021
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials
Nicola A Hanania, Scott Caveney, Tedi Soule, et al.
Pharmacoepidemiology and Drug Safety
|
April 3, 2008
Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
Andrew J P Cooper, Sally Lettis, Charlotte L Chapman, et al.
The Journal of Allergy and Clinical Immunology. Global
|
October 2, 2023
IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial
Courtney Crim, Sally Stone, Valerie Millar, et al.
Annals of the American Thoracic Society
|
December 10, 2014
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD
Courtney Crim, Mark T Dransfield, Jean Bourbeau, et al.
The Lancet. Respiratory Medicine
|
January 17, 2014
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials
Mark T Dransfield, Jean Bourbeau, Paul W Jones, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 26, 2020
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
MeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
Respiratory Research
|
April 29, 2021
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
Dave Singh, Gerard J Criner, Mark T Dransfield, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
International Journal of Chronic Obstructive Pulmonary Disease
|
February 2, 2018
Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials
David B Rubin, Harris A Ahmad, Michael O'Neal, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
November 23, 2018
Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
Salman H Siddiqui, Ian D Pavord, Neil C Barnes, et al.
Chest
|
January 14, 2012
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial
Nicola A Hanania, Gregory Feldman, Wolfgang Zachgo, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
July 1, 2021
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials
Nicola A Hanania, Scott Caveney, Tedi Soule, et al.
Pharmacoepidemiology and Drug Safety
|
April 3, 2008
Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
Andrew J P Cooper, Sally Lettis, Charlotte L Chapman, et al.
The Journal of Allergy and Clinical Immunology. Global
|
October 2, 2023
IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial
Courtney Crim, Sally Stone, Valerie Millar, et al.
Annals of the American Thoracic Society
|
December 10, 2014
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD
Courtney Crim, Mark T Dransfield, Jean Bourbeau, et al.
The Lancet. Respiratory Medicine
|
January 17, 2014
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials
Mark T Dransfield, Jean Bourbeau, Paul W Jones, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 26, 2020
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
MeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
Respiratory Research
|
April 29, 2021
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
Dave Singh, Gerard J Criner, Mark T Dransfield, et al.
Page
of 3